We are live on ! Find out more
CGON icon

CG Oncology

226 hedge funds and large institutions have $6.66B invested in CG Oncology in 2026 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 92 increasing their positions, 72 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

174% more call options, than puts

Call options by funds: $272M | Put options by funds: $99.2M

28% more repeat investments, than reductions

Existing positions increased: 92 | Existing positions reduced: 72

12% more capital invested

Capital invested by funds: $5.93B → $6.66B (+$730M)

1.92% more ownership

Funds ownership: 104.38%106.3% (+1.9%)

8% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 37

3% less funds holding

Funds holding: 233226 (-7)

17% less funds holding in top 10

Funds holding in top 10: 1210 (-2)

Holders
226
Holders Change
-7
Holders Change %
-3%
% of All Funds
2.73%
Holding in Top 10
10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-16.67%
% of All Funds
0.12%
New
34
Increased
92
Reduced
72
Closed
37
Calls
$272M
Puts
$99.2M
Net Calls
+$173M
Net Calls Change
+$46.9M
Name Holding Trade Value Shares
Change
Change in
Stake
RI
1
RTW Investments
New York
$605M +$100M +1,529,782 +22%
T. Rowe Price Investment Management
2
T. Rowe Price Investment Management
Maryland
$470M -$6.77M -103,490 -2%
DC
3
Decheng Capital
California
$453M
BlackRock
4
BlackRock
New York
$445M +$77.9M +1,192,108 +24%
Wellington Management Group
5
Wellington Management Group
Massachusetts
$378M -$3.04M -46,481 -0.9%
Fidelity Investments
6
Fidelity Investments
Massachusetts
$296M +$25.9M +396,649 +11%
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$270M +$9.94M +152,030 +4%
TCM
8
TCG Crossover Management
California
$261M
Vanguard Portfolio Management
9
Vanguard Portfolio Management
Pennsylvania
$246M +$24.2M +370,099 +12%
State Street
10
State Street
Massachusetts
$244M +$51.7M +790,536 +30%
Vanguard Capital Management
11
Vanguard Capital Management
Pennsylvania
$236M +$18.5M +283,168 +9%
FCMV
12
Foresite Capital Management VI
California
$168M +$9.68M +148,100 +7%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$153M +$36.4M +556,413 +35%
SFCM
14
Seven Fleet Capital Management
California
$134M +$118M +1,810,478 +2,390%
EC
15
EcoR1 Capital
California
$106M +$25.6M +392,300 +36%
DT
16
DV Trading
Illinois
$102M
APM
17
Avidity Partners Management
Texas
$99.4M +$7.19M +110,000 +9%
Franklin Resources
18
Franklin Resources
California
$93.3M -$12.7M -194,125 -13%
AllianceBernstein
19
AllianceBernstein
Tennessee
$93M +$5.5M +84,062 +7%
Morgan Stanley
20
Morgan Stanley
New York
$83.6M +$42.9M +656,896 +126%
ACA
21
Acorn Capital Advisors
New York
$80.4M +$65.3K +999 +0.1%
FCMV
22
Foresite Capital Management V
California
$76.7M +$4.9M +75,000 +7%
LGM
23
Logos Global Management
California
$71M +$27.8M +425,000 +74%
Bank of America
24
Bank of America
North Carolina
$70M -$30.4M -464,446 -32%
UBS Group
25
UBS Group
Switzerland
$69.5M -$21.9M -334,283 -25%

CGON Hedge Fund Activity: Q2 2026 in Review

226 of the 8,274 institutional investors tracked by Wall St. Rank reported a position in CG Oncology (CGON) for Q2 2026, worth a combined $6.66B — up 12% from $5.93B a quarter earlier.

Sellers outnumbered buyers: 37 funds closed out of CGON and 34 opened new positions — a net loss of 3 holders — while 72 trimmed existing stakes and 92 added.

The largest buyer was Seven Fleet Capital Management, adding an estimated $118M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $67.7M sold.

  • 226 institutional investors held CG Oncology (CGON) as of Q2 2026, down from 233 in Q1 2026.
  • Funds reported $6.66B of CG Oncology stock for Q2 2026, up 12% quarter-over-quarter.
  • 34 funds opened new CG Oncology positions in Q2 2026 and 37 closed out, a net change of -3 holders.
  • The largest CG Oncology buyer in Q2 2026 was Seven Fleet Capital Management, an estimated $118M added.
  • The largest CG Oncology seller in Q2 2026 was Driehaus Capital Management, an estimated $67.7M sold.

Based on aggregated 13F filings for Q2 2026.